×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Zydus Lifesciences Limited | 27454.0 | 3847.0 | 25883.0 | 3.82 | 1,03,582 | 22.2 |
| LUPIN LTD. | 57627.3 | 21280.7 | 57085.9 | 46.48 | 88738 | 24.0 |
| FORTIS HEALTHCARE LTD. | 4730.4 | 518.8 | 4330.3 | 0.69 | 71400 | 77.6 |
Zydus Lifesciences Limited, with Security Code 532321, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,579.3 | 2,955.7 | 2,159.3 | 2,371.3 | 3,332.4 | 4,160.2 | 2,620.6 | 2,515.9 | 5,819.6 | 2,588.3 |
| Expenses | 1,806.8 | 1,814.7 | 1,509.9 | 1,672.2 | 1,763.2 | 1,787.3 | 1,678.4 | 1,867.4 | 2,046.9 | 2,002.9 |
| Operating Profit | 772.5 | 1,141.0 | 649.4 | 699.1 | 1,569.2 | 2,372.9 | 942.2 | 648.5 | 3,772.7 | 585.4 |
| OPM % | 29.95% | 38.6% | 30.07% | 29.48% | 47.09% | 57.04% | 35.95% | 25.78% | 64.83% | 22.62% |
| Other Income | 47.4 | 82.4 | 534.5 | 106.8 | 352.5 | 106.6 | 326.7 | 77.5 | 185.4 | 157.1 |
| Interest | 85.0 | 89.7 | 90.9 | 103.9 | 106.2 | 115.4 | 95.9 | 97.2 | 155.4 | 137.6 |
| Depreciation | 119.9 | 121.2 | 124.9 | 127.7 | 130.6 | 130.6 | 133.7 | 131.6 | 128.0 | 130.0 |
| Profit before tax | 818.8 | 1,012.5 | 968.1 | 574.3 | 1,693.5 | 2,233.5 | 1,039.3 | 497.2 | 3,674.7 | 474.9 |
| Tax % | -20.2% | -22.9% | -16.8% | -21.6% | -16.6% | -23.9% | -24% | -5.3% | -23.4% | 19% |
| Net Profit | 490.7 | 780.9 | 805.0 | 450.4 | 1,405.2 | 1,700.8 | 789.8 | 470.6 | 2,813.7 | 384.7 |
| EPS in Rs | 4.85 | 7.71 | 7.96 | 4.45 | 13.89 | 16.9 | 7.85 | 4.68 | 0 | 3.82 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,362.3 | 5,010.6 | 5,139.6 | 4,368.8 | 4,505.2 | 5,533.8 | 6,207.5 | 5,237.0 | 5,269.1 | 6,527.9 |
| Expenses | 3,406.3 | 3,755.0 | 3,634.3 | 3,222.7 | 3,402.8 | 3,903.3 | 4,123.5 | 3,775.6 | 3,881.5 | 4,407.5 |
| Operating Profit | 956.0 | 1,255.6 | 1,505.3 | 1,146.1 | 1,102.4 | 1,630.5 | 2,084.0 | 1,461.4 | 1,387.6 | 2,120.4 |
| OPM % | 21.92% | 25.06% | 29.29% | 26.23% | 24.47% | 29.46% | 33.57% | 27.91% | 26.33% | 32.48% |
| Other Income | 38.5 | -563.5 | 21.8 | 54.0 | 37.7 | 156.4 | 63.2 | 68.2 | 57.5 | -139.0 |
| Interest | 32.8 | 27.7 | 18.1 | 8.7 | 19.8 | 34.6 | 32.2 | 25.1 | 32.0 | 76.6 |
| Depreciation | 181.6 | 178.6 | 179.8 | 184.2 | 194.8 | 205.3 | 215.3 | 233.6 | 229.0 | 237.9 |
| Profit before tax | 780.1 | 1,087.1 | 1,343.4 | 1,007.2 | 925.5 | 1,547.0 | 1,899.7 | 1,270.9 | 1,184.1 | 1,886.5 |
| Tax % | -25% | -28.2% | -16.3% | -22.5% | -23.1% | -20.8% | 23% | 29.4% | 15.2% | -25.3% |
| Net Profit | 631.2 | 358.2 | 1,133.6 | 803.2 | 789.9 | 1,246.1 | 1,482.5 | 920.2 | 1,026.2 | 1,243.7 |
| EPS in Rs | 6.15 | 2.93 | 10.74 | 7.91 | 7.8 | 11.69 | 14.11 | 9.06 | 10.17 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 19% |
| 3 Years: | 24% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 32% |
| 3 Years: | 74% |
| TTM: | 68% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 21% |
| 3 Years: | 35% |
| 1 Year: | -17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 26% |
| 3 Years: | 2% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 21% |
| 3 Years: | 35% |
| 1 Year: | -17% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|